Droperidol injection
DrugAbout 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.
Other names: D
NCT Number: NCT05401058
The aim of this multicenter, prospective, randomized, double-blind and large sample study is to explore the preventive effect of low-dose droperidol on POD in elderly patients after non-cardiac surgery, providing new approach for reducing the incidence of POD and improving the prognosis and quality of life.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
The first Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
About 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.
Other names: D
About 30min before the end of operation, Normal saline 0.5ml will be administered by intravenous injection.
Other names: S
Time frame: 7 days after operation
Incidence of delirium within 7 days after operation
Time frame: From the end of operation to 7 days after opertation
Severity of Postoperative delirium
Time frame: From the end of operation to 7 days after opertation
Delirium-free days
Time frame: From end of operation to discharge, an average of 1 week
Postoperative hospital duration
Time frame: 30 days and 6 months after surgery
cognitive function at 30 days and 6 months
RenJi Hospital
Other
Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery: A Randomized, Double-blind, Placebo-controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05612347
Colonic Diseases, Colorectal Adenoma
Birmingham, Alabama, United States
View Trial DetailsNCT05489237
Digestive System Disease, Digestive System Diseases
Miami, Florida, United States
View Trial DetailsNCT07076641
Digestive System Disease, Digestive System Diseases
Lyon, France
View Trial DetailsNCT06271538
Colonic Disease, Colonic Diseases
Kubang Kerian, Kelantan, Malaysia
View Trial Details